statistiche ricercatore

GROSSI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	6.881
EU - Europa	5.352
AS - Asia	4.587
SA - Sud America	596
AF - Africa	86
OC - Oceania	5
Continente sconosciuto - Info sul continente non disponibili	4
Totale	17.511

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	6.717
IT - Italia	3.369
SG - Singapore	2.116
CN - Cina	959
HK - Hong Kong	788
IE - Irlanda	574
BR - Brasile	498
VN - Vietnam	338
GB - Regno Unito	278
RU - Federazione Russa	244
FR - Francia	242
SE - Svezia	206
DE - Germania	156
FI - Finlandia	109
IN - India	81
MX - Messico	73
CA - Canada	71
BD - Bangladesh	56
JP - Giappone	42
IQ - Iraq	39
AR - Argentina	35
PL - Polonia	33
TR - Turchia	33
UA - Ucraina	29
ZA - Sudafrica	27
AT - Austria	26
NL - Olanda	24
ES - Italia	21
PK - Pakistan	18
SA - Arabia Saudita	18
UZ - Uzbekistan	15
VE - Venezuela	15
EC - Ecuador	14
PH - Filippine	11
BE - Belgio	10
DZ - Algeria	10
JO - Giordania	10
KE - Kenya	9
LT - Lituania	9
CL - Cile	8
EG - Egitto	8
MA - Marocco	8
PY - Paraguay	8
TN - Tunisia	8
ID - Indonesia	7
NG - Nigeria	7
AE - Emirati Arabi Uniti	6
TH - Thailandia	6
UY - Uruguay	6
CO - Colombia	5
OM - Oman	5
PE - Perù	5
EU - Europa	4
KZ - Kazakistan	4
MD - Moldavia	4
PA - Panama	4
TT - Trinidad e Tobago	4
AU - Australia	3
AZ - Azerbaigian	3
CH - Svizzera	3
ET - Etiopia	3
IL - Israele	3
KG - Kirghizistan	3
MY - Malesia	3
NI - Nicaragua	3
NP - Nepal	3
PS - Palestinian Territory	3
AL - Albania	2
AO - Angola	2
BG - Bulgaria	2
BO - Bolivia	2
GE - Georgia	2
GR - Grecia	2
JM - Giamaica	2
LB - Libano	2
NO - Norvegia	2
PT - Portogallo	2
QA - Qatar	2
RS - Serbia	2
SY - Repubblica araba siriana	2
TW - Taiwan	2
BB - Barbados	1
BH - Bahrain	1
BZ - Belize	1
CG - Congo	1
CR - Costa Rica	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DM - Dominica	1
DO - Repubblica Dominicana	1
GA - Gabon	1
GT - Guatemala	1
HR - Croazia	1
KH - Cambogia	1
KI - Kiribati	1
KW - Kuwait	1
LA - Repubblica Popolare Democratica del Laos	1
ML - Mali	1
MN - Mongolia	1
RO - Romania	1
Totale	17.507

Salva come PNG Salva come JPEG

Città	#
Milan	2.465
San Jose	1.391
Singapore	1.105
Hong Kong	774
Ashburn	579
Dublin	574
Dallas	480
Princeton	435
The Dalles	305
Fairfield	300
Boardman	264
Council Bluffs	242
Beijing	239
Rome	227
Lauterbourg	218
Wilmington	199
Chicago	160
Nyköping	160
Chandler	131
Ho Chi Minh City	127
San Diego	115
Woodbridge	112
London	111
Seattle	100
Los Angeles	98
Houston	93
Ogden	86
Hanoi	85
Helsinki	84
Santa Clara	81
Cambridge	75
New York	63
Ann Arbor	56
São Paulo	53
Como	45
Mexico City	45
Orem	37
Munich	34
Tokyo	31
Warsaw	30
Guangzhou	29
Frankfurt am Main	28
Nuremberg	24
Pune	23
Brooklyn	22
Denver	22
Norwalk	22
Salt Lake City	22
San Francisco	22
Atlanta	20
Shanghai	20
Tampa	20
Da Nang	19
Hangzhou	19
Toronto	19
Chennai	18
Chiswick	18
Baghdad	17
Kilburn	16
Stockholm	16
Montreal	15
Phoenix	15
Rio de Janeiro	15
Turku	15
Vienna	15
Jacksonville	14
Johannesburg	14
Shenzhen	14
Washington	14
Zhengzhou	14
Buffalo	13
Redmond	13
Amsterdam	12
Boston	12
Tashkent	12
Tianjin	12
Poplar	11
Amman	10
Belo Horizonte	10
Curitiba	10
Miami	10
Wuhan	10
Brussels	9
Dhaka	9
Düsseldorf	9
Elk Grove Village	9
Falkenstein	9
Genoa	9
Manchester	9
Ankara	8
Biên Hòa	8
Nairobi	8
Nha Trang	8
Prescot	8
Saronno	8
Sterling	8
Turin	8
Acton	7
Changsha	7
Detroit	7
Totale	12.653

Salva come PNG Salva come JPEG

Nome	#
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin	175
Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines.	165
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)	141
Afatinib for the treatment of non-small cell lung cancer	139
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis	125
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis	120
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy	119
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer	114
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial	114
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study	114
A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic	111
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer	110
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation	109
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer	108
Afatinib for the treatment of advanced non-small-cell lung cancer	107
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study	107
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines	105
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation	102
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)	102
Advances in treatment of mesothelioma	99
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy	97
Alternating bolus and continuous infusion 5-fluorouracil: A strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients	97
Novel treatment strategies for early-stage lung cancer: The oncologist’s perspective	97
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial	95
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	93
Liquid biopsy in non-small cell lung cancer: highlights and challenges	93
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer	92
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer	92
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	91
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy	90
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)	89
Exosomes: a new horizon in lung cancer	89
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers	89
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial	88
Hematopoietic growth factors in lung cancer	88
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial	88
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer	88
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine	87
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects	85
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743	85
Vinflunine for the treatment of non-small cell lung cancer	85
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial	85
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib	85
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study	84
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer	84
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?	84
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial	83
Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification	83
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study	83
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab	83
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer	83
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)	83
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib	83
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer	82
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study	82
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries	82
Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries	82
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy	82
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells	81
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study	81
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors	81
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer	81
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients	80
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis	80
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells	80
Ramucirumab: preclinical research and clinical development	80
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy	79
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers	79
Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study	79
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy	79
COVID-19 vaccination in patients with classic Kaposi’s sarcoma	79
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial	78
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer	78
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds	78
Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study	78
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study	77
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer	77
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?	77
The clinical management of early and advanced colorectal cancer	77
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?	77
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG	77
Systemic drug therapy of malignant pleural mesothelioma.	76
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy	76
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition	76
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?	76
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study	76
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer	76
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer	75
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients	75
IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions	75
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.	75
Tag-based next generation sequencing: A feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients	75
IDH signalling pathway in cholangiocarcinoma: From biological rationale to therapeutic targeting	75
Update on the treatment of small cell lung cancer (SCLC)	75
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases	74
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer	74
Impact of bmi on survival outcomes of immunotherapy in solid tumors: A systematic review	74
Management of malignant pleural effusions	74
Managing patients with lung cancer - Common international guidelines must be developed	73
Targeting kras in solid tumors: Current challenges and future opportunities of novel kras inhibitors	73
Totale	8.933

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	134.874
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	134.874

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	8	0	0	0	0	0	0	0	0	0	0	0	8
2021/2022	1.833	0	5	1	0	430	190	192	151	232	186	105	341
2022/2023	1.155	225	49	70	40	78	310	4	69	84	176	16	34
2023/2024	3.882	483	689	646	787	905	116	26	52	146	12	3	17
2024/2025	3.119	17	29	584	41	37	221	101	99	499	220	208	1.063
2025/2026	7.889	393	647	495	975	549	327	1.902	513	1.055	566	327	140
Totale													18.050